Table 2 Prevalence of retinal pigment epithelial tear, worsening of retinal haemorrhage, and intraocular inflammation in the intravitreal aflibercept (IVA) and intravitreal brolucizumab (IVBr) groups at 3 months after the first treatment
IVA group | IVBr group | P value | |
|---|---|---|---|
Eyes | 49 | 34 | |
RPE tear | 5(10%) | 1(3%) | 0.3930 |
Worsening of retinal hemorrhage | 4(8%) | 1(3%) | 0.6440 |
Intra ocular inflammation | 0 | 5(15%) | 0.0096 (95%CI:0–0.5096) |